San Antonio Breast Cancer Symposium.
Collingridge
David
D
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D034261:Epothilones / Q000008:administration & dosage; D000068338:Everolimus; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013629:Tamoxifen / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D014230:Triazoles / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D034261:Epothilones; D009570:Nitriles; D043823:Taxoids; D014230:Triazoles; D013629:Tamoxifen; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D000077289:Letrozole; D000068338:Everolimus; C430592:ixabepilone; D000068878:Trastuzumab; D005472:Fluorouracil; D020123:Sirolimus